China's National Medical Products Administration accepted the registration application of Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Shanghai Zhaohui Pharmaceutical for its dobutamine drug.
The medication is intended to be used for the enhancement of myocardial contractility in acute circulatory insufficiency and the observation of stress echocardiography.
Hong Kong-listed shares of the pharmaceutical company closed nearly 4% lower on Monday.
Price (HKD): $14.78, Change: $-0.54, Percent Change: -3.52%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments